# Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

> **NCT04837196** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Advanced Malignancies
- Advanced Cancer

## Interventions

- **DRUG:** ASP7517
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04837196
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2024-06-21
- **Final completion:** 2024-06-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04837196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04837196, "Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04837196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*